Volume 126, Issue 5 pp. 888-895
MELANOMA, SARCOMA

Fifty years of progress in surgical oncology: Melanoma

Daniel G. Coit MD

Corresponding Author

Daniel G. Coit MD

Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Correspondence Daniel G. Coit, MD, Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA. 

Email: [email protected]

Search for more papers by this author
Charlotte E. Ariyan MD, PhD

Charlotte E. Ariyan MD, PhD

Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Search for more papers by this author
First published: 10 September 2022

Abstract

This paper outlines the scientific and clinical advances in the treatment of melanoma over the past 50 years. Among the highlights of progress, the dominant themes include evidence-based reduction in the extent and morbidity of surgical procedures in patients with local or regional melanoma without compromising end results, and the introduction of effective systemic therapy, specifically targeted therapy matched to patients based on specific tumor mutations, and immune checkpoint blockade. Management of advanced disease has also changed dramatically, due to improved understanding of the genomic variability of the disease as well as continuing improvements in imaging.

DATA AVAILABILITY STATEMENT

N/a.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.